Regeneron Pharmaceuticals, Inc.;Institute for Research in Biomedicine (IRB);Yale University
发明人:
Sean Stevens,Andrew J. Murphy,Richard Flavell,Elizabeth Eynon,Jorge Galan,Tim Willinger,Markus Manz,Anthony Rongvaux,George D. Yancopoulos
申请号：
US16352674
公开号：
US20190297862A1
申请日:
2019.03.13
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A mouse with a humanization of the miL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene； and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.
